triamcinolone acetonide

(redirected from Azmacort HFA)

triamcinolone acetonide

; Adcortyl corticosteroid preparation (10mg/mL) for intrasynovial, intra-articular or soft-tissue injection

triamcinolone acetonide (topical) (as´ətō´nīd),

n brand names: Aristocort, Flutex, Kenalog, Kenalog in Orabase, Oracort, Triacet, Triderm, others;
drug class: topical corticosteroid;
action: interacts with steroid cytoplasmic receptors to induce antiinflammatory effects; possesses antipruritic and antiinflammatory actions;
uses: treatment of psoriasis, eczema, contact dermatitis, pruritus; special dental paste used to treat nonviral inflammatory oral lesions, including aphthous stomatitis, lichen planus, and cicatrical pemphigoid.
References in periodicals archive ?
The Company plans to maintain its research and development focus, increasing product development investments 35% - 40% from 2004, excluding the effect of the one-time, $38 million in-process R&D write-off associated with purchase of Azmacort HFA.
55 per share, associated with the reversal of the Company's deferred tax asset valuation allowance during 2004, (ii) $38 million charge associated with the Azmacort HFA acquisition, which had a negative income statement impact of $0.
08 Impact of One-Time Events Azmacort HFA acquisition: -In-process R&D (38,000) (0.